LOGIN  |  REGISTER
Assertio

Teleflex to Present at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum: Virtual

March 07, 2023 | Last Trade: US$234.14 1.24 -0.53

WAYNE, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 12:00 p.m. (ET).

A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, QuikClot®, LMA®, Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.

Contact:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development

This email address is being protected from spambots. You need JavaScript enabled to view it.
610-948-2836

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB